Table 2 Characteristics of cancer chemotherapy patients receiving alkylant agents
From: Risk factors for oral mucositis in paediatric oncology patients receiving alkylant chemotherapy
Gender | ||
|---|---|---|
Group 1 (mucositis) n = 241 n (%) | Group 2 (no mucositis) n = 96 n (%) | |
Male | 146 (60.5) | 67 (69.7) |
Female | 95 (39.5) | 29 (30.3) |
χ2 Mantel-Haenszel = 2.50 p = 0.11 | ||
Diagnosis | ||
Group 1 (mucositis) n = 241 n (%) | Group 2 (no mucositis) n = 96 n (%) | |
Cerebral tumors | 70 (30.7) | 27 (28.1) |
Germinal tumors | 78 (32.4) | 22 (22.9) |
Sarcoma | 68 (28.2) | 36 (37.5) |
Hodgkin | 9 (3.7) | 11 (11.5) |
Other | 12 (5.0) | - (--) |
χ2 = 13.46 p < 0.01 | ||
Chemotherapy Regimens | ||
Group 1 (mucositis) n = 241 n (%) | Group 2 (no mucositis) n = 96 n (%) | |
Melphalan® | 24 (9.9) | 20 (20.8) |
Busulfan® | 153 (63.5) | 34 (35.4) |
Other | 64 (26.6) | 42 (43.8) |
χ2 = 22.42 p < 0.001 | ||